Dimitrios Volanis

ORCID: 0000-0002-4040-2835
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Bladder and Urothelial Cancer Treatments
  • Urinary and Genital Oncology Studies
  • Prostate Cancer Diagnosis and Treatment
  • Urological Disorders and Treatments
  • Urologic and reproductive health conditions
  • Epigenetics and DNA Methylation
  • Cancer, Hypoxia, and Metabolism
  • Ureteral procedures and complications
  • Urinary Bladder and Prostate Research
  • Esophageal Cancer Research and Treatment
  • Aerospace Engineering and Energy Systems
  • Prostate Cancer Treatment and Research
  • Aerospace and Aviation Technology
  • Genital Health and Disease
  • Colorectal Cancer Screening and Detection
  • Bone and Dental Protein Studies
  • Cancer-related Molecular Pathways
  • Advanced Radiotherapy Techniques
  • COVID-19 and healthcare impacts
  • Urinary Tract Infections Management
  • Abdominal Trauma and Injuries
  • Trauma and Emergency Care Studies
  • MicroRNA in disease regulation
  • Circular RNAs in diseases
  • Pelvic floor disorders treatments

The Royal Free Hospital
2024

University College London
2024

Royal Free London NHS Foundation Trust
2019-2023

Cambridge University Hospitals NHS Foundation Trust
2016

Addenbrooke's Hospital
2014-2015

University of Crete
2011-2012

General Hospital Asklepieio Voulas
2010-2012

National Hellenic Research Foundation
2010

Hippocration General Hospital
2007

10.1016/j.euo.2020.12.002 article EN European Urology Oncology 2021-01-12

miRNAs are noncoding RNAs that posttranscriptionally regulate gene expression. Altered expression and function have been observed in bladder cancer. We analyzed the profile of a group involved cancer angiogenesis, tumor cell proliferation, suppressor inhibition, epithelial-mesenchymal transition metastasis activation. Prognostic diagnostic value, validated targets were further examined.Using quantitative real-time polymerase chain reaction 77 cases matched associated normal samples...

10.1016/j.juro.2012.03.122 article EN The Journal of Urology 2012-06-15

Ta grade 3 (G3) non–muscle-invasive bladder cancer (NMIBC) is a relatively rare diagnosis with an ambiguous character owing to the presence of aggressive G3 component together lower malignant potential component. The European Association Urology (EAU) NMIBC guidelines recently changed risk stratification for from high intermediate, high, or very risk. However, prognostic studies on carcinomas are limited and inconclusive. To evaluate value categorizing compared G2 T1 carcinomas. Individual...

10.1016/j.euo.2023.01.004 article EN cc-by European Urology Oncology 2023-01-19

The objective of this study was to analyze the expression profile angiogenic components, vascular endothelial growth factor-A (VEGFA), basic fibroblast factor-2 (FGF2), osteopontin (OPN) and ras homolog gene family, member C (RHOC), in urothelial cell carcinoma (UCC) urinary bladder examine their role as candidate diagnostic biomarkers. Using qPCR, 77 samples UCC matched tumor-associated normal were investigated determine four components. correlation between expression, patient survival...

10.3892/or.2012.1948 article EN cc-by-nc Oncology Reports 2012-08-03

We previously identified common differentially expressed (DE) genes in bladder cancer (BC). In the present study we analyzed depth, expression of several groups these DE genes.Samples from 30 human BCs and their adjacent normal tissues were by whole genome cDNA microarrays, qRT-PCR Western blotting. Our attention was focused on cell-cycle control DNA damage repair genes, related to apoptosis, signal transduction, angiogenesis, as well cellular proliferation, invasion metastasis. Four...

10.1371/journal.pone.0018255 article EN cc-by PLoS ONE 2011-04-05

To investigate the clinical and pathological trends, over a 10-year period, in robot-assisted laparoscopic prostatectomy (RALP) UK regional tertiary referral centre.In all, 1 500 consecutive patients underwent RALP between October 2005 January 2015. Prospective data were collected on clinicopathological details at presentation as well surgical outcomes compared time.The median (range) age of throughout period was 62 (35-78) years. The proportion preoperative high-grade cases (Gleason score...

10.1111/bju.13513 article EN BJU International 2016-04-29

Mixed adenoneuroendocrine carcinoma (MANEC) is a rare tumour found predominantly in the gastrointestinal tract. Comprising adenocarcinomatous and neuroendocrine components, MANEC have been reported bladder. We report first case to our knowledge of arising urethra. A 62-year-old woman presented with suburethral mass. Initial excision mass revealed it be MANEC. Immunohistochemistry staining was positive for CK20 synaptophysin associated tumours. Cross-sectional imaging ruled out metastases...

10.1136/bcr-2018-227948 article EN BMJ Case Reports 2019-03-01
Coming Soon ...